Merck (MRK) Reports Q1 Earnings: What Key Metrics Have to Say

For the quarter ended March 2025, Merck (MRK) reported revenue of $15.53 billion, down 1.6% over the same period last year. EPS came in at $2.22, compared to $2.07 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $15.39 billion, representing a surprise of +0.93%. The company delivered an EPS surprise of +3.26%, with the consensus EPS estimate being $2.15.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Merck performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Sales- Oncology- Keytruda - U.S. $4.31 billion versus the four-analyst average estimate of $4.47 billion. The reported number represents a year-over-year change of +4.6%. Sales- Oncology- Keytruda - International: $2.90 billion compared to the $3.08 billion average estimate based on four analysts. The reported number represents a change of +2.4% year over year. Sales- Oncology- Alliance revenue- Lynparza - U.S. $145 million versus $121.96 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.4% change. Sales- Oncology- Alliance revenue- Lynparza - International: $168 million versus $178.66 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7% change. Sales- Oncology- Keytruda: $7.21 billion compared to the $7.55 billion average estimate based on four analysts. The reported number represents a change of +3.7% year over year. Sales- Hospital Acute Care- Zerbaxa: $70 million compared to the $63.07 million average estimate based on three analysts. The reported number represents a change of +25% year over year. Sales- Oncology- Alliance Revenue- Lynparza: $312 million versus the three-analyst average estimate of $300.62 million. The reported number represents a year-over-year change of +6.9%. Sales- Oncology- Alliance revenue- Lenvima: $258 million versus the three-analyst average estimate of $234.33 million. The reported number represents a year-over-year change of +1.2%. Sales- Hospital Acute Care- Bridion: $441 million compared to the $410.18 million average estimate based on three analysts. The reported number represents a change of +0.2% year over year. Sales- Animal health: $1.59 billion versus the three-analyst average estimate of $1.61 billion. The reported number represents a year-over-year change of +5.1%. Sales- Hospital Acute Care- Prevymis: $208 million versus $190.69 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.5% change. Sales- Oncology- Alliance revenue- Reblozyl: $119 million compared to the $101.77 million average estimate based on three analysts. The reported number represents a change of +67.6% year over year. View all Key Company Metrics for Merck here>>>Shares of Merck have returned -10.6% over the past month versus the Zacks S&P 500 composite's -5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks